Triumph Capital Management Humanigen, Inc Transaction History

Triumph Capital Management

  • $234 Million
  • Q1 2024

A detailed history of Triumph Capital Management transactions in Humanigen, Inc stock. As of the latest transaction made, Triumph Capital Management holds 17,000 shares of HGEN stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,000
Previous 17,000 -0.0%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 08, 2023
SELL
$0.12 - $0.23 $4,800 - $9,200
-40,000 Reduced 70.18%
17,000 $2,000
Q4 2022

Jan 31, 2023
BUY
$0.09 - $0.2 $3,600 - $8,000
40,000 Added 235.29%
57,000 $6,000
Q3 2022

Nov 01, 2022
BUY
$0.15 - $3.02 $2,550 - $51,340
17,000 New
17,000 $3,000

Others Institutions Holding HGEN

# of Institutions
4
Shares Held
558K
Call Options Held
0
Put Options Held
0
View Full List

About HUMANIGEN, INC

HGEN Quotes by TradingView
  • Ticker HGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,661,000
  • Description
  • Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...
More about HGEN
Track This Portfolio

Track Triumph Capital Management Portfolio

Follow Triumph Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Triumph Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Triumph Capital Management with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email